Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28042144 | 0.86 | MAPK8 (0.51) | KDM4EMEN1LMNAKMT2AEGLN1 | |
| SCHEMBL7014947 | 0.85 | EGLN1 (0.64) | KDM4EMEN1LMNAKMT2AEGLN1 | |
| SCHEMBL7010267 | 0.82 | LMNA (0.61) | KDM4EMEN1LMNAKMT2AEGLN1 | |
| SCHEMBL7018585 | 0.82 | NPC1 (0.69) | KDM4EMEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL7013158 | 0.82 | LMNA (0.53) | KDM4EMEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL7022295 | 0.81 | KDM4E (0.56) | KDM4EMEN1LMNAKMT2AEGLN1 | |
| SCHEMBL7017456 | 0.81 | POLB (0.64) | EGLN1EGFRMMP13ALDH1A1HPGD | |
| SCHEMBL7016470 | 0.79 | MEN1 (0.71) | KDM4EMEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL7017409 | 0.78 | EGLN1 (0.53) | KDM4EMEN1LMNAKMT2AEGLN1 | |
| SCHEMBL7022585 | 0.78 | KDM4E (0.64) | KDM4EMEN1LMNAKMT2AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605614-B2 | Anti-hepatitis or anti-herpes | BIOCHEM PHARMA INC. (CA) | 2003-08-12 | — | — | US | claimed |
| JP-2002537396-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | BIOCHEM PHARMA INC. | 2002-07-25 | — | — | US | claimed |
| US-6340690-B1 | INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS | BIO-CHEM PHARMA INC. (CA) | 2002-01-22 | — | — | US | claimed |
| EP-1155017-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Shire Biochem Inc. (CA) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050424-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BIOCHEM PHARMA INC. (CA) | 2000-08-31 | — | — | WO | claimed |
| EP-1751155-B1 | SUBSTITUTED AZACHINAZOLINES HAVING AN ANTIVIRAL ACTION | BAYER HEALTHCARE AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-6605614-B2 | Anti-hepatitis or anti-herpes | BIOCHEM PHARMA INC. (CA) | 2003-08-12 | — | — | US | disclosed |
| EP-1155017-B1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | SHIRE BIOCHEM INC (CA) | 2003-01-15 | — | — | EP | disclosed |
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | BIOCHEM PHARMA INC. | 2002-07-25 | — | — | US | disclosed |
| US-6340690-B1 | INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS | BIO-CHEM PHARMA INC. (CA) | 2002-01-22 | — | — | US | disclosed |
| EP-1155017-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Shire Biochem Inc. (CA) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050424-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BIOCHEM PHARMA INC. (CA) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | HAVCR2, MAVS, NTPCR | KDM4E 3460/4885MEN1 4721/4885LMNA 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.